| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 1764 | 2018 |
| Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study JE Salem, A Manouchehri, M Moey, B Lebrun-Vignes, L Bastarache, ... The Lancet Oncology 19 (12), 1579-1589, 2018 | 790 | 2018 |
| 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology … AR Lyon, T López-Fernández, LS Couch, R Asteggiano, MC Aznar, ... European heart journal 43 (41), 4229-4361, 2022 | 751 | 2022 |
| Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis JJ Moslehi, JE Salem, JA Sosman, B Lebrun-Vignes, DB Johnson The Lancet 391 (10124), 933, 2018 | 701 | 2018 |
| Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised … G Cayla, T Cuisset, J Silvain, F Leclercq, S Manzo-Silberman, ... The Lancet 388 (10055), 2015-2022, 2016 | 376* | 2016 |
| Abatacept for severe immune checkpoint inhibitor–associated myocarditis JE Salem, Y Allenbach, A Vozy, N Brechot, DB Johnson, JJ Moslehi, ... New England Journal of Medicine 380 (24), 2377-2379, 2019 | 318 | 2019 |
| Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial M Rosenzwajg, R Lorenzon, P Cacoub, HP Pham, F Pitoiset, K El Soufi, ... Annals of the rheumatic diseases 78 (2), 209-217, 2019 | 304 | 2019 |
| Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology MP Bonaca, BA Olenchock, JE Salem, SD Wiviott, S Ederhy, A Cohen, ... Circulation 140 (1), 80-91, 2019 | 297 | 2019 |
| Statin therapy is associated with lower prevalence of gut microbiota dysbiosis S Vieira-Silva, G Falony, E Belda, T Nielsen, J Aron-Wisnewsky, ... Nature 581 (7808), 310-315, 2020 | 286 | 2020 |
| Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study DB Johnson, A Manouchehri, AM Haugh, HT Quach, JM Balko, ... Journal for immunotherapy of cancer 7 (1), 1-9, 2019 | 237 | 2019 |
| Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio‐oncology guidelines J Alexandre, J Cautela, S Ederhy, GL Damaj, JE Salem, F Barlesi, ... Journal of the American Heart Association 9 (18), e018403, 2020 | 192 | 2020 |
| Cardiovascular toxicities associated with ibrutinib JE Salem, A Manouchehri, M Bretagne, B Lebrun-Vignes, JD Groarke, ... Journal of the American College of Cardiology 74 (13), 1667-1678, 2019 | 190 | 2019 |
| Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin I Gouin‐Thibault, X Delavenne, A Blanchard, V Siguret, JE Salem, ... Journal of Thrombosis and Haemostasis 15 (2), 273-283, 2017 | 159 | 2017 |
| Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes L Genser, D Aguanno, HA Soula, L Dong, L Trystram, K Assmann, ... The Journal of pathology 246 (2), 217-230, 2018 | 158 | 2018 |
| Immune checkpoint inhibitor–associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution C Anquetil, JE Salem, B Lebrun-Vignes, DB Johnson, AL Mammen, ... Circulation 138 (7), 743-745, 2018 | 148 | 2018 |
| A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention SC Wei, WC Meijers, ML Axelrod, NAAS Anang, EM Screever, ... Cancer discovery 11 (3), 614-625, 2021 | 141 | 2021 |
| A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis DB Johnson, WJ McDonnell, PI Gonzalez-Ericsson, RN Al-Rohil, ... Nature medicine 25 (8), 1243-1250, 2019 | 139 | 2019 |
| Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation LS Nguyen, M Vautier, Y Allenbach, N Zahr, O Benveniste, ... Drug safety 42, 813-825, 2019 | 128 | 2019 |
| Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology A Molinaro, P Bel Lassen, M Henricsson, H Wu, S Adriouch, E Belda, ... Nature Communications 11 (1), 5881, 2020 | 124 | 2020 |
| Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase L Xiao, JE Salem, S Clauss, A Hanley, A Bapat, M Hulsmans, Y Iwamoto, ... Circulation 142 (25), 2443-2455, 2020 | 121 | 2020 |
Javid MoslehiUniversity of California, San Francisco (UCSF)Verified email at ucsf.edu
